Advertisment
Loading...

Introducing StemJournal Senior Editor: Fredrik Lanner, PhD

Dark blue cells on pale blue background

22 April 2021 | Amsterdam, NL – We are pleased to introduce our new Senior Editor Fredrik Lanner, PhD, who joins from the Karolinska Institute in Stockholm, Sweden where his research focuses on early human developmental and stem cell biology combined with the exciting possibilities of generating clinically relevant cell types for novel cell therapy strategies.

Introducing Fredrik Lanner as new Senior Editor of StemJournal

[by Carmel McNamara, IOS Press]

Amsterdam, NL – We are pleased to introduce our new Senior Editor Fredrik Lanner, PhD, who joins from the Karolinska Institute in Stockholm, Sweden where his research focuses on early human developmental and stem cell biology combined with the exciting possibilities of generating clinically relevant cell types for novel cell therapy strategies. 

 

Of his new role, Fredrik says: "I’m excited to get this opportunity to be part of initiating and shape a new open access journal as an editor on my favorite topic, stem cells!"

Dr. Lanner is Assistant Professor at the Karolinska Institute and leads his research group on Developmental and Reparative Stem Cell Biology at the Department of Clinical Science, Intervention and Technology and at the Ming Wai Lau Center for Reparative Medicine. He undertook PhD studies on developmental vascular biology with Professor Filip Farnebo at Karolinska Institute and subsequently performed his postdoctoral research in Janet Rossant’s laboratory at the SickKids Research Institute in Toronto, Canada where he studied early mouse development and stem cell biology. He then returned to Karolinska Institute in 2012 to start his independent line of research combining human developmental biology with translational pluripotent stem cell-based reparative medicine.

Fredrik’s research interest is rooted in early human developmental and stem cell biology combined with the exciting possibilities of generating clinically relevant cell types for novel cell therapy strategies. The lab is currently dissecting how totipotency, pluripotency and first lineage specifications are regulated and specified in the human embryo. In addition to such fundamental studies we have high translational ambitions and have established our first clinically compliant hESC (KARO1) at the Karolinska Institute. Using stem cell-derived retinal pigment epithelial cells we are further developing treatment strategies for Age-Related Macular degeneration with the first upcoming clinical trial aiming to start in 2022.

A donated human embryo (in red)
A donated human embryo, three days following fertilization – at this point of development, all cells are thought to be uncommitted totipotent cells which in the coming days will be restricted to pluripotent embryonic epiblast and the crucial extra-embryonic lineages.

We are very pleased to welcome Fredrik as he joins the senior team, ready to welcome submitted papers. He comments: "Human developmental biology, stem cell research, and reparative medicine are areas of research that currently develop with blazing speed which is inspiring – but careful scrutiny of new and sometimes spectacular findings is therefore needed more than ever. I hope to contribute to this process as a Senior Editor of StemJournal."